| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-05-09 | Sanofi (France) Exscientia (UK) | research - R&D - licensing | Metabolic diseases | Research agreement | ||
| 2017-05-09 | Alnylam Therapeutics (USA - MA) | nomination | Nomination | |||
| 2017-05-09 | Takeda Pharmaceutical (Japan) GammaDelta Therapeutics (UK) | gamma delta (??) T cell therapies | cancers including solid tumors, autoinflammatory diseases | development | Cancer - Oncology - Autoimmune diseases | Development agreement |
| 2017-05-09 | Tmunity Therapeutics (USA - PA) | chief business officer | nomination | Cancer - Oncology - Autoimmune diseases - Infectious diseases | Nomination | |
| 2017-05-08 | Ipsen (France) Sanofi (France) | five consumer healthcare products including Prontalgine® | pipeline acquisition | Pipeline acquisition | ||
| 2017-05-08 | Pharmaxis (Australia) Chiesi (Italy) | Bronchitol® (mannitol) | cystic fibrosis | distribution | Rare diseases - Genetic diseases | Distribution agreement |
| 2017-05-08 | Regeneron Pharmaceuticals (USA - NY) Sillajen (Republic of Korea) | REGN2810 in combination with Pexa-Vec (pexastimogene devacirepvec) | renal cell carcinoma | clinical research | Cancer - Oncology | Clinical research agreement |
| 2017-05-08 | Array BioPharma (USA - CO) Merck&Co (USA - NJ) | binimetinib and Keytruda® (pembrolizumab) | colorectal cancer | clinical research | Cancer - Oncology | Clinical research agreement |
| 2017-05-08 | Inovio Pharmaceuticals (USA - PA) Regeneron Pharmaceuticals (USA - NY) | REGN2810, INO-5401, INO-9012 | glioblastoma | clinical research | Cancer - Oncology | Clinical research agreement |
| 2017-05-08 | Crispr Therapeutics (Switzerland - UK) the Massachusetts Institute of Technology (MIT) (USA - MA) | Lipid Nanoparticle (LNP) technologies | licensing | Technology - Services | Licensing agreement | |
| 2017-05-08 | Audentes Therapeutics (USA - CA) | chief scientific officer | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2017-05-05 | Seattle Genetics (USA - WA) Immunomedics (USA - NJ) | sacituzumab govitecan (IMMU-132) | solid tumors | licensing | Cancer - Oncology | Termination of an agreement |
| 2017-05-05 | Lundbeck (Denmark) | restructuring | Restructuring | |||
| 2017-05-05 | MDxHealth (Belgium) GROW - the School for Oncology and Developmental Biology at the Maastricht University Medical Centre (The Netherlands) | (epi)genetic-based assays | research - R&D | Cancer - Oncology | Research agreement | |
| 2017-05-04 | Karo Bio (Sweden) - Pfizer (USA - NY) | novel small molecule RORgamma modulators for the treatment of autoimmune diseases | autoimmune diseases | R&D | Autoimmune diseases | Milestone |
| 2017-05-04 | Epizyme (USA - MA) GSK (UK) | novel small molecule therapeutics targeting histone methyltransferases including GSK3326595 | R&D - commercialisation | Cancer - Oncology | Milestone | |
| 2017-05-04 | Swedish Orphan Biovitrum - SOBI (Sweden) | president and chief executive officer | nomination | Rare diseases - Genetic diseases - Hematological diseases | Nomination | |
| 2017-05-04 | Crispr Therapeutics (Switzerland - UK) | president and chief executive officer | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2017-05-03 | Servier (France) Miragen Therapeutics (USA -CO) | three drug candidates, including two of miRagen’s lead programs (miR-208 and miR-15/195), one additional target , MicroRNA-92 and MRG-110 | cardiovascular diseases | R&D commercialisation | Cardiovascular diseases | R&D agreement |
| 2017-05-03 | AstraZeneca (UK) Pieris Pharmaceuticals (Germany) | Anticalin® platform, including PRS-060 | asthma | development - commercialisation | Allergic diseases – Inflammatory diseases – Respiratory diseases | Development agreement |
